Pura Vida Investments LLC Sells 122,575 Shares of Pulmonx Co. (NASDAQ:LUNG)

Pura Vida Investments LLC decreased its holdings in shares of Pulmonx Co. (NASDAQ:LUNG - Free Report) by 24.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 387,200 shares of the company's stock after selling 122,575 shares during the period. Pulmonx makes up 8.3% of Pura Vida Investments LLC's holdings, making the stock its 4th largest position. Pura Vida Investments LLC owned 0.98% of Pulmonx worth $2,629,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in LUNG. 272 Capital LP acquired a new stake in Pulmonx in the third quarter worth $25,000. R Squared Ltd acquired a new stake in Pulmonx during the 4th quarter worth $46,000. SG Americas Securities LLC lifted its holdings in Pulmonx by 27.0% during the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company's stock worth $106,000 after acquiring an additional 3,310 shares in the last quarter. American Century Companies Inc. lifted its holdings in Pulmonx by 8.8% during the fourth quarter. American Century Companies Inc. now owns 34,738 shares of the company's stock worth $236,000 after acquiring an additional 2,810 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Pulmonx by 4.9% in the fourth quarter. Rhumbline Advisers now owns 53,503 shares of the company's stock valued at $363,000 after acquiring an additional 2,488 shares during the period. Institutional investors and hedge funds own 91.04% of the company's stock.

Insiders Place Their Bets

In related news, Director Glendon E. French III sold 20,000 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total transaction of $157,000.00. Following the transaction, the director now directly owns 991,974 shares in the company, valued at approximately $7,786,995.90. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Geoffrey Beran Rose sold 5,779 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.13, for a total transaction of $41,204.27. Following the sale, the insider now directly owns 285,278 shares in the company, valued at $2,034,032.14. This trade represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 147,986 shares of company stock valued at $1,143,673 in the last 90 days. 5.70% of the stock is currently owned by insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Citigroup started coverage on Pulmonx in a report on Monday, March 10th. They set a "buy" rating on the stock. Jefferies Financial Group started coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a "buy" rating on the stock. Morgan Stanley assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They issued an "equal weight" rating for the company. Wells Fargo & Company dropped their price objective on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Wednesday, December 11th. Finally, D. Boral Capital started coverage on shares of Pulmonx in a research note on Monday, March 10th. They issued a "buy" rating and a $17.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $13.36.

Pulmonx Stock Down 1.5 %

Pulmonx stock traded down $0.10 during mid-day trading on Thursday, reaching $6.72. The company's stock had a trading volume of 112,104 shares, compared to its average volume of 327,571. The business's 50 day simple moving average is $7.21 and its 200 day simple moving average is $6.93. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. Pulmonx Co. has a 12 month low of $5.46 and a 12 month high of $10.01. The company has a market capitalization of $267.43 million, a price-to-earnings ratio of -4.67 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The company had revenue of $23.77 million during the quarter, compared to analysts' expectations of $22.29 million. As a group, research analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.